Three startup models, a 144-day spread

You can read a sponsor’s timeline expectations. You can hear at a conference that a site across town opened a study in six weeks. What you cannot do is watch how they did it: which team touched the budget first, who noticed the contract had stalled, whether anyone was tracking the whole path or whether four people each did their part and the order happened to work out.

One published analysis comes close to that comparison. Researchers followed 308 site activations across 13 multicenter trials between 2019 and 2024, all moving through the same coordinating structure, and recorded what startup support each one had (Hillery et al., 2025).

The trials using all three elements activated in a median of 133 days. The trials without the standardized lean workflow ran to a median of 277. Both of the slower panels still had two of the three elements, so this is not a comparison of supported against unsupported.

Before that gap does any work, it needs its limits stated. These were 13 different trials, not randomized arms. The intervention combination was chosen at trial level by trial leadership, and the groups differ in therapeutic area, network, start date and site cohort. Two COVID-19 treatment trials sit in the fastest group. The authors call the work exploratory and list trial design, personnel changes, approvals and technology problems among the things that could move these numbers.

So this is an association between ways of running startup, not proof that one causes the other.

What separated the groups

Medians are of trial medians within each panel, not of individual site activation times. Intervention combinations were selected at trial level in an exploratory convenience sample of 13 trials (Hillery et al., 2025).

The three elements were a standardized workflow with benchmarks set in advance, an electronic tracking system, and dedicated site navigators who checked in with each site weekly.

In the all-three-elements panel, 31% of site activations completed within 90 days. In the other two panels, none did.

The observed median gap between the full package and the no-navigator group was 58 days. Read that as a subtraction and nothing more. Tracking was present in all three groups, so this study cannot tell you what tracking contributed, and the combinations were assigned by trial rather than chosen site by site.

What the result does support is narrower and still useful: running startup as a connected workflow, with someone whose job is to move studies through it, is worth testing at your own site.

The interval between the timestamps

The practical problem sits in what each stage leaves behind.

IRB review has a name, a committee, a submission date and an approval letter. Contract execution has a signature page. Regulatory has a binder. Each of those finishes, and finishing leaves a record.

The period where coverage analysis becomes a budget, and the budget becomes a contract, is not one activity. It is several teams’ work overlapping in an order that changes from study to study. Check your own system, whether that is a CTMS or a spreadsheet: does it record when a stage completed, and separately when the next stage picked it up? Where only the first exists, the difference between them cannot be seen at all.

If that interval has no name at your site, it is harder to give it an owner. If it has no owner, it is harder to measure. And what is not measured is difficult to improve, however well the individual stages are running.

That chain is a management heuristic rather than a law, but it is cheap to test.

A worked example, hypothetically

To make the shape concrete, consider a protocol amendment that adds an imaging timepoint. What follows is illustrative rather than observed, and how much of it applies depends on your protocol, billing status and staffing model.

If the imaging changes what can be billed, the coverage analysis has to be revisited. Budget work that depends on that classification may then need reworking, and contract terms that depend on the budget may follow. Depending on the change, regulatory and consent documents may also need updating.

Say each team involved completes its own part in a few days.

The question worth asking is who is tracking the elapsed time across all of them.

If the answer at your site is a recurring meeting, that is worth sitting with. A meeting reports status. Reporting that contracts is waiting on budget does not move the study, and the interval between those two teams belongs to neither of them.

None of this implies anyone is failing. It describes a coordination limit, and coordination limits do not respond to working harder. They tend to get worse as study volume rises.

The chain running underneath it

The handoff gaps are not random. They sit at specific joins, and the joins are where one team’s output has to be good enough for the next team to start.

The joins, rather than the activities on either side of them.

The order runs like this. Medicare coverage analysis informs the budget, because you cannot price what you have not classified. The budget supports contract negotiation. And coverage analysis and budget together enable the trial management system build. Coverage analysis takes a small share of the overall timeline and shapes how smoothly everything after it runs, which is a poor trade if it is the stage your team squeezes when the calendar is tight (WCG, 2026).

Worth saying plainly: not every pause is waste. Many are approvals doing their job. The ones worth examining are the pauses that persist because they always have.

And nothing in the published evidence quantifies these gaps or shows they are the largest component of activation time. The Hillery analysis measured total activation, not handoff latency. That the gaps are where most of the time goes is a hypothesis this article is putting to you, not a finding any source establishes. You can start testing that hypothesis with two dates at each handoff.

The problem is not newly discovered

A team at the University of South Florida mapped their activation process across 78 trials and reported that, contrary to expectation, IRB approval was not the longest step. Contract negotiation and budget negotiation were, at averages of 54.9 and 46.3 days (Martinez et al., 2016). A separate analysis of 689 non-cancer trials at the University of Kansas Medical Center found the stage covering regulatory documents, budget and contract ran to a median of 98 days, against 55 days for IRB review (Cernik et al., 2021).

Both are old, both are single institutions, and the Kansas window closes in 2018, before the single-IRB mandate and before the pandemic changed how sites work. Neither is a benchmark for your site today.

Their value is that they were published, available, and pointing at contracts and budgets more than a decade ago. Startup is still described across the industry as a persistent challenge.

Our reading is that a problem documented this long is not waiting on more evidence.

What some centers have built

Two academic medical centers whose current service pages describe this directly are UCSF and Duke. Both centralize some combination of coverage analysis, budgeting, contracting, system build and startup navigation.

UCSF’s office covers coverage analysis, budget development and negotiation, and protocol calendar build. Duke’s Office of Clinical Research, created in 2012 when the school restructured central research support, provides a broad set of study services.

Their service lists are worth reading against your own process, with one caution: an office existing does not tell you why it was created, and these offices differ from each other. Duke’s current materials include IRB-related review and system support, so this is not a pattern of centralizing everything except IRB.

What is common is that each pulled work which had been distributed across functions into a single place with a single address. The site navigators in the Hillery analysis are a smaller version of the same move, carried by one person rather than a department.

If you cannot fund a central office

Many sites cannot, and pointing at Duke is not useful advice for a site running eight studies with six coordinators.

The transferable part is the ownership rather than the office, and ownership costs less than headcount.

Give the interval a name your team uses out loud. It does not matter what you call it. A thing that can be referred to can appear on an agenda.

Give it one owner rather than a committee. Someone whose explicit responsibility is elapsed time, as distinct from the people responsible for each task. This can be part of an existing role.

Record two dates at each handoff. When a stage finished, and when the next one picked it up. The second is the one to check for. If both dates exist in your records, 10 recent activations are a useful first diagnostic slice rather than a statistically sound sample, which is the point. If the pickup date was never recorded, use your next 10 instead.

Look for pauses that exist by habit. A review that has never once changed an outcome, or a document that waits for a weekly meeting because it always has. Those cost nothing to remove.

Where policy allows, start dependent work in parallel. Worth checking whether a sequence you treat as fixed is actually required, or just the order things arrived in.

Five questions about your own activation

The takeaway

The evidence does not prove that the gaps are where most activation time goes. What it shows is that trials run as a connected workflow, with someone responsible for moving studies through, finished startup faster in one large exploratory analysis, and that two independent institutions found contracts and budgets rather than IRB at the top of their delay lists more than a decade ago.

The post Where Study Activation Time Actually Goes, and Why Your Timeline Doesn’t Show It appeared first on TrialConnx.

Study startup has quietly become its own discipline. The work of getting a trial ready to open, the regulatory packages, the budgets, the contracts, the system builds, has outgrown the informal way most sites still run it. Nothing exposes that gap faster than a protocol amendment that lands after the startup package goes out but before the site opens to accrual.

The amendment itself is often small. The damage is in everything that has to re-sync around it. The numbers bear it out: most sites handle 3 to 10 pre-activation amendments a month, and those amendments most often add 4 to 6 weeks to activation (AACI, 2026). The symptom is a delay. The cause is that startup has become a coordination problem most sites have no system for.

First, the proof

The data is blunt enough to settle the “is this a real problem” question in one line.

A trial that has not opened yet, that has not screened a single patient, is already absorbing that. And the cause is rarely the science. The damage is in everything that has to re-sync around a change, with no shared way to manage the re-syncing. That pattern, where the coordination load rather than the clinical work sets the pace, is the same one we traced in When Study Startup Becomes a Bottleneck.

The fix is three capabilities

The emerging guidance on amendments runs to a list of recommendations, and a list is how good ideas stall in a startup queue. Distilled, it comes down to three capabilities. Build these and the rest follow.

Shared Readiness: a definition of “ready,” not a trickle of documents

Readiness sounds obvious until you watch it fail. A site receives the protocol one day, the budget grid a few days later, the consent template the following week, and a “minor” lab manual change after that. Each arrival restarts a piece of the build. The fix is a complete, internally consistent amendment package with a coversheet that lists every changed document and version date, and an explicit “no change” where a document was not touched. The site does not start the affected work until the package is whole. That single rule removes most of the rework that quietly eats the calendar.

Shared Language: one scale everyone reads the same way

When a site, a sponsor, and an IRB each describe an amendment in their own terms, every handoff carries a translation cost. A shared impact scale removes it. The same change gets the same label, and the label tells everyone what may proceed. This is the capability a site can adopt entirely on its own, and it is where consent and version control go wrong most often, a theme we covered in Why Site IRB Submissions Fail.

Shared Clock: turnaround commitments and one owner of status

The last capability is the one most sites never formalize. Concrete windows work: acknowledge a complete package within 2 business days, return a feasibility read within 5, answer blocking questions within 5, and escalate when a window slips (AACI, 2026). Paired with a single named owner of amendment status, the question “can we start, or do we wait” stops bouncing between inboxes and gets a reliable answer.

Rank amendments by activation impact

The middle capability is the one most teams can adopt this week, with no one’s permission. The tool is a single ladder for an amendment’s impact, so “is this a big deal” stops being a fresh argument every time. Here is the simple version we use with sites.

A site can adopt a ladder like this internally without waiting on partners. A shared scale turns a recurring judgment call into a fast, defensible one, and that changes how a startup queue moves.

Where this breaks at scale

Picture a startup coordinator on a Tuesday morning. Four studies sit open on her desk, all in startup. Study ABC-201 just landed its third protocol version, and she is no longer certain the consent she sent to the IRB last week is the current one. Study XYZ-105 has a budget amendment stuck in legal, and the sponsor is asking why activation has slipped. Two more are waiting on a feasibility read she has not had time to write.

Nothing on her desk is hard. Every item is a small, reasonable decision. The problem is that no single place tells her which version is live on which study, what is ready, and who owes the next move. So she spends the morning reconstructing that picture from email threads instead of clearing work. Multiply that one morning across a quarter, and you get the survey numbers.

Here is the part no checklist solves. Readiness, language, and a clock are agreements. Agreements work on one study. They get harder to sustain the moment a site is running three, four, five startups at once, each with its own document versions, its own pending amendments, its own clock.

That is the real reason startup has become its own discipline. Not because the steps are hard, but because holding the state across many parallel startups is more than a spreadsheet or a calendar reminder can hold. The capabilities only stick when something holds the state for everyone: which version is live, what is ready, who owes the next move, and how long it has been waiting. It is also why a system built to run an open trial does not cover this work, the gap we walked through in Why Your CTMS Isn’t Built for Study Startup.

Put a rough number on it. On a Phase II or III trial, a single day of delay runs about $40,000 (Tufts CSDD). So two weeks of amendment churn, the low end of what most sites report, works out to roughly half a million dollars of delay cost on a single study by that benchmark, before a patient is ever enrolled. And money is the smaller cost. A site that opens two months behind its peers loses enrollment share on competitive trials, and sponsors remember which sites activate fast. The weeks lost before a trial opens quietly shape which trials a site is offered next.

A quick self-check

How a site digs out

The way out is not a transformation program, and our coordinator does not need to wait for one. It is three moves, in order, and the first needs no one’s permission.

First, she counts. For each startup, how many pre-activation amendments arrived, and how many weeks each one added. It takes an afternoon with old emails, and it changes the conversation, because most sites have never put a number on this. You cannot manage a delay you have never measured. Where to begin: the six startup metrics worth tracking.

Then, the team adopts one language. The impact ladder goes up on the wall, and “is this a big deal” stops being a fresh argument on every amendment. A junior coordinator can label a change cosmetic or critical and defend the call, while a named owner on each startup keeps a running list of which version is live. None of this needs a sponsor’s sign-off. It is simply how the site talks to itself.

Finally, the state stops living in her memory. The first two moves get a site surprisingly far, but they share a ceiling, the same one she hit on Tuesday morning. Across many concurrent startups, which version is live, what is ready, and who owes the next move is more than any one person or spreadsheet can hold reliably. The capabilities only stick when something holds that state for the whole team, visible to everyone at once.

You know it is working when the questions change. “Which version is live?” gives way to a few numbers anyone can see: amendments per startup, weeks added, time to clear by impact level, and how often a package arrives complete the first time. When those are the questions a site is asking, the discipline has taken hold.

How amendments should be handled

The three moves get a site surprisingly far, but doing this properly, across a whole portfolio, means letting a system carry what a person cannot. A good one does a specific job. Across every startup a site is running, it keeps one current answer, visible to everyone, to four questions: which protocol version is live, what is ready to work, who owns the next move, and how long it has been waiting. It carries the impact ladder, so a labeled amendment routes itself instead of waiting for a meeting. It holds the clock, so a slipped turnaround surfaces on its own. And it keeps a clean version trail, so the current document is never in question.

The real gains come from doing this once, shared. When the same readiness definition, the same impact labels, and the same clock are visible to the site and to its sponsors, CROs, and IRBs, the coordination cost drops on every side, not just inside the site. That is the difference between a site that survives amendments and one that barely notices them.

The takeaway

The white paper measured a delay. What it points to is a discipline coming into focus. Study startup is no longer a set of tasks one capable person can carry in their head across a few studies. It is a managed process with its own readiness, its own language, and its own clock. The sites that treat it that way will clear amendments while everyone else is still deciding whether the latest version is the one to build against.

If you want a number of your own, start with your last three startups. Count the amendments. Count the weeks. That single exercise tends to change the conversation.

Frequently asked questions

Visual Summary

Get the impact ladder and the key numbers from this post in a swipeable slide deck. Download it or share it with your team.

Sources

• Association of American Cancer Institutes (AACI). Accelerating Clinical Trial Activation: a Collaborative Framework for Managing Pre-Activation Protocol Amendments. June 2026. PDF.
• Smith, Z. P., DiMasi, J. A., and Getz, K. A. (2024). New Estimates on the Cost of a Delay Day in Drug Development. Therapeutic Innovation and Regulatory Science, 58(5), 855-862. Source of the $40,000 per day cost-of-delay figure (authors affiliated with Tufts CSDD).

The post One Amendment, Six Weeks Gone: A Study Startup Saga appeared first on TrialConnx.

Your tech stack already has layers

If you run clinical research at any scale, you already manage multiple systems. An eReg system for regulatory documents. An eConsent platform. A CTMS for trial operations. An EHR that connects clinical care to research. A finance system for invoicing and milestones. Each one covers a specific function. None of them tries to do everything.

Study startup is the one function that still doesn’t have a dedicated layer. Instead, it runs on spreadsheets, email threads, shared drives, and the memory of whoever has been at the institution longest. That gap costs sites 25 to 30 days per study in internal handoffs alone (Tufts CSDD, 2024). It’s not a gap anyone planned. It formed because CTMS platforms expanded into trial management before startup had its own tooling category.

There’s a name for this gap: study startup systems. It’s the missing layer in the clinical tech stack, purpose-built to manage the pre-activation phase that your CTMS was never designed to cover. The question IT leaders are asking isn’t “do we need another system?” It’s “is the gap costing us more than filling it would?” For most sites running five or more concurrent studies, the answer is already clear. We explored why in When Study Startup Becomes a Bottleneck.

What OnCore, Medidata, Veeva, and WCG do well

This isn’t about what’s wrong with your CTMS. It’s about understanding what each platform was built for so you can see where the boundary is.

OnCore is the dominant CTMS in academic medical centers. It manages study calendars, patient visit tracking, coverage analysis, and financial milestones. For AMCs running NCI-designated cancer center portfolios, OnCore is deeply embedded in post-activation workflows.

Medidata Rave CTMS serves large CROs and sponsors managing multi-site global trials. It excels at enrollment tracking, randomization, site performance metrics, and sponsor-side reporting across hundreds of sites.

Veeva CTMS (part of the Veeva Vault Clinical Suite) targets sponsor and CRO operations with strong document management integration, milestone tracking, and regulatory intelligence across the clinical development lifecycle.

WCG eResearch (formerly Velos eResearch) serves academic medical centers and health systems with study management, regulatory tracking, and financial operations. For sites already using WCG’s IRB services, eResearch provides an integrated path from regulatory approval to trial operations.

All four platforms share the same architectural assumption: they manage what happens after a site activates. After regulatory approval is in hand. After contracts are executed. After the site is green-lit for enrollment.

The pattern is consistent: your CTMS picks up at activation. Everything before that point is the startup phase. And it’s the startup phase where sites lose an average of 25 to 30 days in internal handoffs alone (Tufts CSDD, 2024).

Where a startup tool sits in your clinical technology stack

Here’s the part that matters most for IT planning. A study startup tool doesn’t sit on top of your CTMS. It sits beside it, covering a different phase of the same lifecycle. The boundary is clean: everything from feasibility through site activation lives in the startup tool. Everything from activation through study close lives in the CTMS.

How data flows between systems

This is the question every CIO asks first, and the answer is simpler than most expect.

The two systems operate on sequential phases. They don’t need to share real-time data because they’re rarely active on the same study at the same time. The handoff happens once: at activation.

What the startup tool creates

• Regulatory approval dates and document status
• Contract execution dates and key terms
• Budget approval status and negotiation history
• Training completion records and delegation log status
• Feasibility response data and PI confirmation
• Time-in-stage and handoff duration metrics

What your CTMS needs at activation

• Confirmation that regulatory approval is complete
• Executed contract and approved budget
• Completed training and delegation documentation
• Green-light confirmation that the site is ready to enroll

The integration model

For most implementations, the integration is a defined handoff, not a continuous data sync. When activation readiness is confirmed, the study moves into the CTMS workflow. This can be as simple as a status notification or as structured as an API-based trigger.

Most sites start with manual or notification-based handoff and move to API integration only when volume demands it. The point: you don’t need to plan a six-month integration project to get started.

The IT concerns (and honest answers)

If you’ve been burned by a clinical technology implementation before, these are the questions you’re already thinking about. Here are direct answers.

What happens when the 89-day gap stays open

Most of these consequences don’t surface in a single study. They compound across three, five, ten concurrent startups until the pattern is impossible to ignore.

• Activation timelines stretch without explanation. The protocols aren’t harder. The sponsors aren’t slower. But every study takes longer than it should because coordination overhead grows faster than study count.
• Budget work starts late. At one AMC, budget negotiation couldn’t begin until Day 72 of a 120-day activation target. Sixty percent of the timeline was consumed before core financial work could start.
• IRB submissions get rushed. When coordinators are stretched across multiple startups, first-pass approval rates drop from 78% to 52%. Each revision cycle adds 13 or more days.
• Feasibility responses slow down. New opportunities sit in a queue while the team is buried in active startup work. Every delayed response is a study your site may not get.
• Status meetings replace actual work. What starts as a 90-minute weekly check-in becomes 6+ hours of reconstructing reality across spreadsheets, email, and hallway conversations.

These aren’t hypotheticals. They’re patterns we’ve seen at sites running three or more concurrent startups without a dedicated system for the pre-activation phase. The CTMS captures the downstream effects, but the root cause is upstream, in the 89 days before activation.

What changes for site teams

Technology decisions happen in IT offices. But the impact lands on coordinators, study managers, and PIs. Here’s what actually changes in daily workflows when a startup tool runs alongside your CTMS.

The coordinator who used to spend Monday mornings reconstructing status across spreadsheets now opens a dashboard. The study manager who scheduled weekly check-ins with four departments now reviews a portfolio view. The PI who asked “are we on track?” and waited two days for an answer gets it in real time.

The CTMS doesn’t change. It still does what it does well. The difference is that studies arrive at activation better prepared, with cleaner documentation, fewer last-minute scrambles, and staff who aren’t already burned out from the startup phase.

What this looks like in practice

Theory is useful. But here’s what this looked like at one site.

Does this sound familiar?

You don’t need to run a formal evaluation to know if the 89-day gap is costing you. You just need to answer a few questions honestly.

If most of these are true, your current setup is working:

• You run fewer than 3 concurrent studies
• Your activation timelines are within industry median for your study phase
• You can answer “where is Study X in startup?” in under 2 minutes
• Your IRB first-pass approval rate is above 70%

If any of these sound familiar, the gap is already costing you:

• You run 5+ concurrent startups
• Activation timelines consistently exceed industry median
• Status updates require weekly meetings with multiple departments
• Staff turnover is connected to startup workload
• Your CTMS has a startup module but your team still uses spreadsheets

Questions for your vendor evaluation

Frequently Asked Questions

These are the questions that come up most during evaluation.

The stack is simpler than you think

Your CTMS manages trials. Your eReg manages documents. Your EHR manages patients. Each system covers its phase. Study startup is the phase that’s been running on workarounds. That’s the 89-day gap.

Filling it doesn’t complicate your stack. It completes it. A study startup system sits beside your CTMS, covers the pre-activation phase, and hands off cleanly at activation. No overlap. No integration required to start.

Map your last three study startups. Count the days between stages. That gap is where the weeks are hiding.

The post How Specialized Study Startup Tools Work Alongside OnCore, Medidata, and Veeva appeared first on TrialConnx.

Startup works fine until it doesn’t

One study in startup? You know every task, every deadline, every contact. The protocol requirements live in your head. You track milestones in a spreadsheet, maybe a shared document. It works because one person can hold the entire picture.

Two studies? More effort, but the same approach holds. You adjust your schedule. You stay late occasionally. The spreadsheet gets another tab.

Then a third study arrives. And something subtle changes. The approach that carried you through the first two isn’t holding up. Tasks slip. Handoffs stall. Feasibility responses that took 3 days now take 9. You spend more time chasing updates than doing the work itself.

This isn’t a competence problem. It’s a coordination limit. Sites don’t hit this wall because they’re disorganized. They hit it because informal coordination has a ceiling, and most sites cross it somewhere between study two and study four.

We explored this pattern in detail in Are Spreadsheets Enough for Tracking Study Startup? The short version: the tool isn’t the issue. The coordination model is.

Five signs startup has become a bottleneck at your site

The bottleneck doesn’t announce itself. It builds gradually. At first, it feels like more work. Then it becomes something else. Here are five signs that startup coordination has crossed from manageable to constraining your site.

1. Feasibility responses are slowing down

Your feasibility coordinator used to turn responses around in 3 business days. Now, with five concurrent startups pulling attention, responses take 9 days. That’s a 200% increase, and it has nothing to do with the complexity of the questionnaires.

What it looks like at the site: new feasibility requests sit in a queue while the coordinator is buried in active startup work for studies already in the pipeline. They’re triaging instead of responding. Every delayed response is a potential study your site doesn’t get.

2. IRB submissions are bouncing back more often

When a regulatory coordinator has time to prepare a complete submission, first-pass approval rates run around 78%. Under the pressure of multiple concurrent startups, that drops to fifty-two percent. The 26-percentage-point gap adds 13 or more days per study in revision cycles.

What it looks like at the site: the regulatory coordinator knows the package isn’t complete. But three other studies need attention this week, so they submit what they have and hope for the best. The revision comes back. Another cycle begins. We covered the seven most common first-submission failures in Why Site IRB Submissions Fail the First Time.

3. Status updates require meetings instead of glances

At two concurrent studies, status meetings take about 1.5 hours per week. At five concurrent studies, that grows to 6 hours per week. A 300% increase in time spent talking about work instead of doing it.

The meeting isn’t the problem. The problem is that nobody can answer “where is Study X in startup?” without assembling everyone in a room. There’s no single view of what’s happening across studies. So you reconstruct the picture from memory, every week, in a conference room.

What it looks like at the site: Monday becomes meeting day. The actual work gets pushed to Tuesday through Friday. And by Friday, you’re already behind for the next Monday update.

4. Activation timelines are stretching without explanation

One research site went from managing 2 concurrent startups to 5 without changing their coordination process. Their median activation time jumped from 72 days to 118. That’s a 64 percent increase. The protocols weren’t harder. The sponsors weren’t slower. The site hit the complexity ceiling.

What it looks like at the site: every study takes longer than it should, but nobody can point to a single reason. The delays are spread across dozens of small handoffs and micro-decisions that don’t show up in any milestone tracker. We explored this breakdown pattern in What Breaks First When Sites Run Multiple Studies in Parallel.

5. Your best people are burning out

According to the ACRP Workforce Survey (2024), thirty-four percent of CRCs cite burnout as their primary reason for leaving clinical research. When startup workload spills into evenings and weekends, that’s not dedication. It’s a system failure being absorbed by individuals.

What it looks like at the site: the person who holds everything together, the one who remembers which study needs what and when, starts looking for a different job. When they leave, the institutional knowledge leaves with them. And the next study startup takes even longer.

Why working harder doesn’t fix a scaling problem

This is where most sites start to feel the shift. The natural response when things slow down is to push harder. Work longer hours. Skip a review step. Ask the coordinator to take on one more study. Maybe hire another person.

But the bottleneck isn’t a staffing problem. It’s an architecture problem.

Study startup involves parallel workstreams: regulatory submissions, contract negotiations, budget creation, feasibility responses. Each study adds a full set. At one study, you’re managing 4 workstreams. At five studies, you’re managing 20, with overlapping dependencies, shared resources, and handoffs that multiply faster than headcount ever could.

The relationship between study count and coordination overhead isn’t linear. It’s closer to exponential. That’s what makes this a scaling problem, not a people problem. How do you track 20 parallel workstreams across spreadsheets, email threads, and shared drives? You don’t. Not well.

For a closer look at where this administrative burden lands, see The Hidden Admin Workload in Study Startup.

The hidden cost of a slow startup

And this is the part that’s easy to miss. A startup bottleneck isn’t an inconvenience. It has real downstream consequences for study quality, site revenue, and staff retention. The costs compound, and most don’t surface until it’s too late to prevent them.

Study quality takes the first hit

According to the ACRP Quality Benchmarking Survey (2023), 67% of protocol deviations in the first 90 days trace back to inadequate startup preparation. Rushed startup means incomplete training, unclear delegation logs, and staff who don’t fully understand the protocol before the first patient walks in.

One site managing 8 studies on compressed timelines saw a 23% protocol deviation rate. After implementing structured startup management with clear stage gates and handoff ownership, deviations dropped to 9%. A sixty-one percent reduction.

Source: ACRP Quality Benchmarking Survey (2023)

Site revenue erodes

Every delayed feasibility response is a potential study your site doesn’t get. Every extended activation timeline is sponsor confidence you’re losing. Sites competing for studies are judged on activation speed. A site that consistently takes 118 days when the industry median is 89 is a site that stops getting selected.

This isn’t abstract. If your feasibility response time has gone from 3 days to 9, sponsors are seeing that. They’re comparing your turnaround against other sites. And they’re making selection decisions based on it.

Staff retention breaks down

One site saw 28% annualized staff turnover before implementing a structured startup approach. After giving coordinators visibility into workload distribution, clear handoff ownership, and proactive escalation paths, turnover dropped to eleven percent. A 61% reduction.

Coordinators don’t leave because the work is hard. They leave because the work feels impossible and nobody can see what they’re carrying. When a coordinator quits, the institutional knowledge leaves with them, and the next startup takes even longer.

We explored this cycle in depth in The Unspoken Tradeoffs Sites Make to Hit Startup Timelines.

What to do about it: a practical framework for sites

Not every site needs the same intervention. The right response depends on where you are: how many concurrent startups you manage, how much visibility you have, and how fast you need to scale. Here’s a three-tier framework matched to your situation.

Tier 1: Process fixes (zero cost, high impact)

Best for: Sites running 2-3 concurrent startups

Start by mapping the startup timeline for your last 3 studies. Not the total days. Break it into stages and measure two things: time in each stage and time between stages. The gaps between stages are where handoff problems hide.

At one academic medical center, the longest single wait was getting in front of the PI: 29 business days. They didn’t need software to fix that. They restructured when the resource meeting happened and eliminated the wait.

Another quick win: decouple sequential steps. Can budget shell creation start before all sponsor information arrives? In most cases, yes. Starting the shell earlier means the budget is closer to ready when the final details come in, instead of starting from zero on Day 72 of a 120-day target.

For guidance on breaking down your startup timeline, see Inside the Study Start-up Timeline.

Tier 2: Visibility improvements (low cost, systematic impact)

Best for: Sites running 3-5 concurrent startups

Process fixes tell you where the problems are. Visibility improvements keep them from coming back. Three things to build:

For a practical starting point, see The Minimal Viable Study Startup Dashboard.

Tier 3: Dedicated startup tooling (investment, transformational impact)

Best for: Sites running 5+ concurrent startups, or planning to grow

At this volume, the coordination complexity exceeds what any spreadsheet or dashboard can handle. Dedicated startup tooling provides:

Not every site needs Tier 3 on day one. But every site running 3 or more concurrent studies should at least be operating at Tier 1. Most aren’t.

What happens when you fix the bottleneck

One academic medical center and NCI-designated cancer center was managing startup across two departments with all ancillary teams. Their activation target: 120 business days. They knew startup felt slow — they didn’t know where the time was going.

What the Data Revealed

When they mapped their first three studies, three things became clear:

• Lab manuals from sponsors weren’t arriving for 3 or more months into the activation process. This delay was invisible in their previous workflow.
• Budget work couldn’t start until Day 72 of a 120-day target. That left 48 days for core work that should have had the full timeline.
• Staff believed they were keeping up. The data showed that in some cases, they were the barrier, without knowing it.

“We weren’t able to start our budget until Day 72 and we are charged with opening within 120 business days.”

Central Office Leadership

What They Changed

Two targeted fixes. Not a complete overhaul.

1. Moved budget shell creation earlier in the process, decoupling it from waiting for complete sponsor information
2. Restructured resource meeting timing to eliminate a 29-day wait to get in front of the PI

Results Within 30 Days

21 days
Saved per study

17.5%
Faster activation

2
Process changes made

“The most important thing for your institution right now is to analyze bottlenecks — are they realistic timelines, has something changed in the process, is there a training issue… The timelines will start decreasing now that we have visibility on tasks.”

Central Office Leadership

Two process changes. One month. Twenty-one days saved per study. They didn’t overhaul everything. They saw where the time was going and fixed the two biggest gaps. That’s the power of visibility over effort.

For a broader look at moving from manual tracking to structured systems, see From Spreadsheets to Systems.

Where does your site stand?

Before you decide what to do next, assess where you are right now. Five questions. Be honest.

For specific metrics to track and what they reveal, see 5 Study Startup Metrics That Actually Predict Delays.

Frequently Asked Questions

Start with the data

Pull the timelines for your last three study startups. Not the total days. Break them into stages. How long did each stage take? How long did work sit between stages waiting for someone to pick it up?

That gap between stages is where your bottleneck lives. You can’t fix what you can’t see.

So start there. Map three studies. Find the gap. Then fix it.

The post When Study Startup Becomes a Bottleneck (And What to Do About It) appeared first on TrialConnx.

Quick Answer

CTMS platforms manage what happens after a study activates: patient screening and enrollment, patient visits, financial milestones. Study startup is a different phase with different workflows, different users, and different bottlenecks. The industry median for startup is 89 days (Tufts CSDD, 2024), and 28 to 34 percent of that time is lost in internal handoffs that CTMS platforms don’t track. Purpose-built startup tools close that gap by giving sites visibility into pre-activation coordination before the first patient is ever enrolled.

What your CTMS does well

CTMS platforms solve real problems. They track patient enrollment. They schedule patient visits. They track financial milestones and data collection workflows. For multi-site trials, they coordinate activities across dozens of locations.

These are valuable functions. If you’re running active studies, your CTMS is probably the system your CRCs and data managers live in daily.

But here’s what these systems have in common: they’re built for what happens after a study activates. After the site is green-lit. After first patient in.

The phase before that? That’s a different problem entirely.

The phase your CTMS doesn’t cover: Study Startup

Before your CTMS even becomes relevant, your site must navigate regulatory submissions, contract redlines, budget creation, feasibility questionnaires, and cross-functional coordination across multiple departments. These are parallel workstreams with daily handoffs, not linear milestones with periodic updates.

Most sites manage this phase with spreadsheets, email threads, and institutional memory. It works when you have one or two studies in startup. It breaks when you have three or more. For a deeper look at where startup time actually goes, see our breakdown in Inside the Study Start-up Timeline.

Two different phases, two different problems

Some CTMS vendors offer startup tracking as an add-on. On paper, it checks the box. In practice, it’s a milestone list bolted onto a system designed for a fundamentally different workflow. Here’s why the architectural mismatch matters:

Study startup requires managing regulatory submissions, contract redlines, budget creation, and feasibility responses in parallel, often across multiple studies at once. CTMS tools track milestones sequentially. That’s the core mismatch.

The cost of this gap: 89 days

Now that the mismatch is clear, here’s what it costs. According to Tufts CSDD (2024), the industry median for study startup is 89 days. Sponsors are increasingly pushing for 60-day activations. That 29-day gap is what sites absorb through workarounds, late nights, and shortcuts.

With no system managing pre-activation coordination, here’s where 89 days go:

The single biggest controllable category is internal handoffs. A regulatory packet waiting on a signature. A budget shell that can’t start because someone is waiting for information from a meeting that hasn’t been scheduled. A feasibility response sitting in a queue because the coordinator is buried in IRB prep for a different study.

What happens when you scale without closing this gap

When startup coordination has no system behind it, problems stay hidden until they become crises. And the more studies you add, the faster it unravels.

The complexity ceiling

One study? You manage it from memory. Two studies? A spreadsheet works. Three or more concurrent startups? That’s where the system breaks.

One research site went from managing 2 concurrent startups to 5 without changing their coordination approach. Their CTMS handled the post-activation side fine. But with nothing managing the pre-FPI chaos, activation time jumped 64 percent, from 72 days to 118. Feasibility responses went from 3 days to 9. Status meetings ballooned from 1.5 hours per week to 6 hours.

We’ve written in detail about this pattern in What Breaks First When Sites Run Multiple Studies in Parallel.

IRB quality erosion

When coordinators are stretched across multiple startups, submission quality drops. Sites that take time to prepare complete packages see a 78 percent first-pass approval rate. Rushed submissions land at 52 percent. That 26-percentage-point gap translates to 13 or more additional days per study in revision cycles.

Most of these revision triggers are predictable and preventable. We covered the seven most common ones in Why Site IRB Submissions Fail the First Time.

Feasibility pipeline damage

Feasibility is your pipeline. Every delayed response is a potential study you don’t get. When coordinators are buried in active startup work, feasibility responses slow from 3 days to 9. That’s not a minor inconvenience. Sponsors notice. For practical strategies to protect your response times, see How to Cut Feasibility Response Times in Half.

Rushed startup damages post-activation too

Here’s the part that connects back to your CTMS. Rushed startup doesn’t just delay activation. It creates problems that show up in your post-activation data: protocol deviations, monitor findings, staff turnover. The damage surfaces in your CTMS, but the root cause is upstream.

Sources: ACRP Quality Benchmarking Survey (2023); ACRP Workforce Survey (2024)

One research site managing 8 concurrent studies on compressed timelines saw a 23 percent protocol deviation rate and 12 monitor observations per study. Staff turnover hit 28 percent annualized. Two resignations in 12 months.

After implementing structured startup management with clear stage gates, handoff ownership, and visibility into workload distribution, their deviation rate dropped to 9 percent. Monitor observations fell to 0.4 per study. Turnover dropped to 11 percent.

The tradeoffs sites make to hit deadlines are real. We explored this pattern in The Unspoken Tradeoffs Sites Make to Hit Startup Timelines.

What purpose-built study startup tools actually do

A dedicated startup tool isn’t a fancier spreadsheet. It’s a system designed specifically for the pre-activation phase, built around the coordination challenges that CTMS platforms were never meant to solve.

What this looks like in practice

One Academic Medical Center’s Experience

A major academic medical center and NCI-designated cancer center mapped their first three studies into a purpose-built startup tool. Within weeks, they discovered something their CTMS had never surfaced: lab manuals from sponsors weren’t arriving for three or more months into the activation process. That delay had been silently inflating their timelines without anyone realizing it.

The data also revealed that budget work couldn’t start until Day 72 of a 120-business-day activation target. Sixty percent of their timeline was consumed before core work could begin.

“We weren’t able to start our budget until Day 72 and we are charged with opening within 120 business days.”

Central Office Leadership

Armed with this visibility, they made two targeted changes: moved budget shell creation earlier in the process and restructured the timing of their resource meetings to eliminate a 29-day wait to get in front of the PI.

21 days
Saved per study

17.5%
Faster activation

30 days
Time to see results

Two process changes. One month. Twenty-one days saved. The tool didn’t change their processes directly. It gave them the visibility to see where the time was going and the data to act with confidence.

For a broader look at moving from manual tracking to structured systems, see From Spreadsheets to Systems.

How to evaluate whether you need a dedicated startup tool

Not every site needs specialized startup software. If you run one or two studies at a time and your activation timelines are within industry benchmarks, your current approach may be working fine.

But if any of the following sound familiar, the gap between your CTMS and your startup workflow is likely costing you weeks per study:

• You run 3 or more concurrent study startups
• Your activation timelines consistently exceed industry median
• You can’t answer “where is Study X in startup?” without calling a meeting or checking multiple spreadsheets
• Your IRB first-pass approval rate is below 70 percent
• Feasibility responses take longer than 5 business days
• Staff are working evenings or weekends to meet startup deadlines

Where do you stand? Phase-specific benchmarks

Source: Phase-specific benchmarks from industry analyses (Tufts CSDD, AACI 2024)

If your Phase 3 startups consistently exceed 89 days, you’re operating below industry median. The question isn’t whether you have a CTMS. It’s whether you have anything managing the 89 days before your CTMS becomes relevant.

For help identifying which metrics matter most, see 5 Study Startup Metrics That Actually Predict Delays. And if you’re still deciding whether your spreadsheet-based approach is sustainable, we addressed that directly in Are Spreadsheets Enough for Tracking Study Startup?

Frequently Asked Questions

Your CTMS manages trials. What manages your startup?

If your team spends more time coordinating startup in spreadsheets than in any formal system, you already know the gap exists. You just haven’t measured it yet.

Audit your last 5 study startups. Measure time in each stage and time between stages. The difference will tell you where the weeks are hiding.

Then ask yourself: is your CTMS solving this problem, or is it waiting for this problem to be solved before it can do its job?

Visual Summary

Get the key points from this post in a swipeable slide deck. Download it or share it with your team.

The post Why Your CTMS Isn’t Built for Study Startup appeared first on TrialConnx.

Quick Answer

IRB review times vary widely across institutions – and revision cycles can add weeks to your timeline. FDA’s FY 2023 inspections consistently cite the same issues: failure to follow the investigational plan, inadequate records, informed consent problems, and safety reporting delays. Common ICF errors include missing signatures, outdated form versions, and failure to re-consent after protocol changes. Sites that implement pre-submission QA protocols can significantly reduce revision cycles and cut weeks from their IRB timelines. The difference isn’t working harder. It’s catching predictable errors before they reach the IRB reviewer’s desk.

What are the most common IRB revision requests sites receive?

IRB revisions feel random until you track them. But FDA inspection data and industry experience reveal clear patterns in what goes wrong—and most issues fall into predictable categories.

What FDA Inspections Reveal (FY 2023)

FDA’s Bioresearch Monitoring (BIMO) program conducted 1,073 inspections in FY 2023, including 681 clinical investigator inspections. The most common violations cited:

Source: FDA BIMO FY 2023 Inspection Data

The Informed Consent Problem

Informed consent issues consistently appear in FDA findings. In 2024, 4 of 7 Warning Letters issued related to IRB activities—including consent form compliance failures. Common ICF errors that trigger revisions:

FDA Warning Letter Patterns (2024)

Recent FDA Warning Letters to clinical investigators and IRBs consistently cite:

Source: FDA BIMO Trends 2023-2024

Every one of these mistakes is preventable with the right pre-submission process. That’s why top-performing sites invest in QA protocols before submission rather than rework cycles after rejection. For a complete view of startup bottlenecks, see How to Fix the Top 5 Study Startup Bottlenecks.

What does IRB first-pass approval rate actually measure?

First-pass approval rate is the percentage of IRB submissions approved without any revision requests. It’s the clearest signal of regulatory submission quality.

IRB Timeline Benchmarks

IRB review timelines vary significantly based on institution, study complexity, and review type:

The real timeline killer isn’t the initial review—it’s revision cycles. A clean submission that goes through in 4 weeks beats a rushed submission that takes 3 weeks but triggers two revision cycles.

Suggested Performance Targets

Based on industry patterns, sites can use these targets to assess their regulatory submission quality:

Note: These are suggested internal targets. Industry-wide first-pass benchmarks are not publicly available.

What Your Rate Tells You

How do top-performing sites minimize revision cycles?

Sites that consistently avoid revision cycles aren’t working harder. They’re working differently. Four strategies separate top performers from the pack.

Strategy 4: Parallel Processing

Sequential workflows kill timelines. While waiting for one document, prepare the next. Top sites run regulatory, contracting, and site preparation in parallel rather than series.

For a complete view of where startup time goes, see Inside the Study Start-up Timeline.

Illustrative Example: What QA Implementation Can Achieve

Context: The AACI 2024 survey found that only 9% of sites meet a 90-day activation target for industry studies, while nearly 60% meet it for NCI-sponsored studies. This gap suggests significant room for process improvement at most sites.

What should a pre-submission QA checklist include?

A comprehensive QA checklist has three components: document completeness, internal consistency, and IRB-specific requirements.

How can sites prepare for predictable IRB questions?

IRBs ask the same questions repeatedly. High-performing sites don’t just answer these questions—they anticipate and address them before they’re asked.

What metrics should regulatory coordinators track?

Tracking the right metrics transforms regulatory performance from reactive to proactive. Focus on both leading indicators (predict problems) and lagging indicators (measure outcomes).

Leading Indicators (Track Weekly)

These predict future problems before they materialize:

Lagging Indicators (Track Monthly)

These measure actual outcomes:

Note: Industry-wide benchmarks for first-pass rates are not publicly available. Focus on improving your own baseline.

For more on building effective dashboards, see The Minimal Viable Study Startup Dashboard.

Stakeholder Takeaways

Frequently Asked Questions

The post Why Site IRB Submissions Fail the First Time: 7 Fixable Mistakes That Add Weeks to Your Timeline appeared first on TrialConnx.

Why do startup timelines force sites to cut corners?

Every PI knows the feeling. A sponsor wants activation in 60 days. Your realistic estimate is 90. You commit to 75 and hope for the best.

This gap between sponsor expectations and site reality creates pressure. That pressure doesn’t disappear. It gets absorbed by your team in the form of shortcuts, deferrals, and quiet compromises that no one documents but everyone feels.

The industry median for study startup is 89 days, according to Tufts CSDD (2024). But sponsors increasingly push for 60-day activations. That 29-day gap has to come from somewhere. It comes from the tradeoffs your team makes when they’re under pressure.

We’ve previously explored where startup time actually goes. Much of it is idle time between tasks. But when you compress a timeline, you don’t just eliminate idle time. You compress the work itself. Tasks get rushed. Quality suffers. Problems get deferred.

What are the 5 most common tradeoffs sites make during startup?

Through analysis of site workflows and conversations with regulatory coordinators across academic and independent sites, five tradeoff patterns appear repeatedly. Most sites make at least three of these on every compressed startup.

Which tradeoffs are acceptable vs. which create real risk?

Not all shortcuts are equal. Some tradeoffs are recoverable with minimal downstream impact. Others compound into serious problems. The skill is knowing the difference before you decide.

Tradeoff	Recoverability	Downstream Risk	Verdict
Skip internal kickoff	Medium	High	Avoid if possible
Incomplete protocol training	High	Medium	Acceptable with plan
Defer SOP updates	Low	High	High risk
Rush regulatory submissions	Medium	Medium	Context-dependent
Overload experienced staff	Low	High	High risk

When Rushing is Actually Reasonable

Some compressed timelines make sense. A competitive enrollment window. A narrow patient population. A sponsor relationship worth preserving. The point isn’t to always push back on aggressive timelines. It’s to make the tradeoffs deliberately.

How do these shortcuts compound over time?

Individual tradeoffs seem manageable. The problem is accumulation. Sites running multiple studies with multiple compressed timelines stack tradeoffs on top of each other. Eventually, the system buckles.

The Invisible Backlog

Every deferred SOP update, every skipped kickoff meeting, every incomplete training session creates work that doesn’t disappear. It just moves to an invisible backlog. This backlog has no owner, no deadline, and no visibility. It surfaces during audits, staff transitions, and crises.

Sites that recognize this pattern often invest in what we call startup metrics dashboards to track not just timeline performance but also quality indicators that reveal accumulating debt.

What can PIs do to make better tradeoff decisions?

The goal isn’t eliminating tradeoffs. That’s unrealistic given industry pressures. The goal is making them consciously, documenting them clearly, and recovering from them quickly.

Case Study: Site B — Northeast Health System

A regional health system provides a clear example of how conscious tradeoff management changes outcomes.

The Problem (2024)

Over 12 months, Site B activated 8 studies with compressed timelines. By Q4, they faced:

The Intervention (Q1 2025)

Site B implemented a structured tradeoff management process:

Results (Q3 2025)

How should sites communicate tradeoffs to sponsors?

Sponsors push for aggressive timelines because they can. Sites that push back effectively don’t just say “we can’t.” They explain the tradeoff and let the sponsor choose.

The Tradeoff Conversation Framework

This reframes the conversation from “site capability” to “sponsor choice.” Most sponsors, when presented with the actual tradeoff, choose the lower-risk option. They just need the information to decide.

Frequently Asked Questions

The post The Unspoken Tradeoffs Sites Make to Hit Startup Timelines appeared first on TrialConnx.

Why does study startup feel slow when running multiple studies in parallel?

You probably feel like your team is working harder than ever, yet studies are taking longer to activate.

This isn’t a “hustle” problem. It’s a secondary complexity problem. When you run one study, your mental map of the tasks is clear. When you run two, it’s a juggle. By study three, the mental map breaks. We previously analyzed how startup time is actually spent, and the findings show that idle time is the biggest killer.

The “slowness” you feel is the time lost between active work. It’s the three days a contract sits on a desk because the regulatory coordinator was buried in an IRB submission for a different trial. In a manual environment, every new study adds a layer of coordination. Eventually, this outweighs the study-advancing work itself.

What is the “Coordination Tax” and why does it hit at study #3?

The Coordination Tax is the total time your team spends on administrative overhead that doesn’t directly advance a study toward activation. This includes status meetings, searching for emails, updating spreadsheets, and asking colleagues “where are we on this?”

In our analysis of site workflows, aligned with ACRP research on study coordinator workload distribution, we found that study #3 is the “Complexity Ceiling.”

At this stage, the human brain can no longer track the multi-dimensional dependencies of three different sponsors and three different IRBs. You stop managing the studies and start managing the trackers. This is why we argue that spreadsheets are rarely enough for high-growth research teams.

Where Startup Time Actually Goes: Industry Breakdown

Understanding where delays originate helps you focus improvement efforts on what you can control.

Source	Typical Days	% of Total	Controllable?
Internal handoffs	25-30	28-34%	High
IRB review cycle	20-28	22-31%	Moderate
Sponsor contract negotiations	18-25	20-28%	Moderate
External vendors (labs, equipment)	12-18	13-20%	Low

Source: Aggregated from Tufts CSDD (2023) and industry benchmarks

What are the warning signs you’ve hit the complexity ceiling?

Before performance collapses entirely, sites exhibit predictable warning signs. Recognizing these early gives you time to adjust before sponsors notice the delays.

Which site operations break first during parallel startup?

When a site hits its complexity ceiling, these four areas usually collapse first. Understanding the sequence helps you prioritize where to build resilience.

How can sites manage multiple studies without losing control?

You don’t need more staff. You need a different operating system. Here’s how high-performing sites scale without proportionally scaling headcount.

Case Study: Site A — Midwest Academic Center

A mid-size academic research center provides a clear example of what happens when a site hits the complexity ceiling and what it takes to break through.

Baseline (Q1 2025)

Performance with 2 concurrent studies was solid:

The Challenge

Over 18 months, Site A scaled from 2 to 5 concurrent studies. By study #4, cracks were visible. By study #5, the system had collapsed.

What Broke (With 5 Studies)

Intervention (Q2-Q3 2025)

The site implemented three core changes over a 90-day period:

Results (Q4 2025)

Industry medians from Tufts CSDD (2023)

What metrics should PIs track across a portfolio?

Does your current reporting tell you which study is actually costing you the most in idle time? Sound familiar? Stop tracking “busyness” and start tracking velocity.

Phase-Specific Activation Benchmarks

Not all studies are equal. These benchmarks measure startup cycle time – from feasibility acceptance to site activation – for each clinical trial phase. Phase 3 pivotal trials naturally take longer to activate than simpler Phase 1 studies. Compare your performance against phase-appropriate targets:

Source: Tufts CSDD (2024)

Key Metrics to Track Weekly

You can start by building a minimal viable startup dashboard to track these core metrics. You don’t need enterprise software to get started. You need the discipline to track and review weekly.

90-Day Implementation Plan

Success in study startup isn’t about working harder. It’s about reducing the friction that stops your team from working. Here’s how to systematically eliminate the Coordination Tax.

Frequently Asked Questions

The post What Breaks First When Sites Run Multiple Studies in Parallel appeared first on TrialConnx.

Why This Matters

Last week, we explored the “5 Study Startup Metrics That Actually Predict Delays”. That post showed what to measure — but not how to interpret the numbers.

This follow-up answers that next big question:

“Okay, we tracked our startup cycle time — but how do we know if it’s actually good?”

Without a benchmark, most teams are flying blind. You might think you’re fast, when you’re just less slow than last quarter.

Real-World Example: Site ABC’s Benchmarking Journey

Let’s walk through a complete example to see how this works in practice.

The Starting Point

Site ABC, a mid-sized academic medical center, started tracking their study startup metrics in Q1 2024. They had no idea if their performance was competitive.

Their Q1-Q3 Data:

Average Cycle Time:

• Q1: 88.6 days
• Q2: 80.1 days
• Q3: 70.9 days

Step 1: Internal Benchmarking (You vs You)

Site ABC calculated their quarter-over-quarter improvement:

• Q1 → Q2: 9.6% reduction (88.6 → 80.1 days)
• Q2 → Q3: 11.5% reduction (80.1 → 70.9 days)
• Overall Q1 → Q3: 20% reduction

What they learned:

• Consistent improvement trend
• Process changes implemented in Q2 showed results in Q3
• But were they actually competitive?

Step 2: External Benchmarking (You vs Industry)

Site ABC compared their Q3 average (70.9 days) against industry benchmarks:

For Phase 2-3 Studies:

• Industry Median: 89 days (Tufts CSDD 2023)
• Top Quartile: <60 days
• Site ABC Phase 2-3 Average: 72.4 days

What they learned:

• 20% faster than industry median
• Still not in the top quartile
• Target identified: Get Phase 2-3 studies under 60 days

Step 3: Contextual Benchmarking (Efficiency Analysis)

They picked Study 006 (Rare Disease, Q3: 73 days) and broke down time allocation:

Time Breakdown:

• Active Work: 52 days
  • Site review & assessment: 8 days
  • Contract negotiation: 12 days
  • Budget finalization: 6 days
  • IRB preparation & submission: 14 days
  • Protocol training & startup: 12 days
• Idle Time: 21 days
  • Waiting for sponsor contract: 9 days
  • Waiting for IRB response: 7 days
  • Internal handoff delays: 5 days

Efficiency Rate: 52 ÷ 73 = 71.2%

What they learned:

• 71% efficiency is above industry average (60%)
• Biggest opportunity: Sponsor contract turnaround (9 days idle)
• Secondary opportunity: Internal handoff process (5 days)

The Action They Took

Based on their benchmarking analysis:

1. Addressed sponsor delays: Created pre-negotiated contract templates → Reduced sponsor wait from 9 to 4 days
2. Fixed internal handoffs: Implemented automated notifications → Reduced handoff delays from 5 to 2 days
3. Set quarterly targets: Goal to reach top quartile (<60 days) by Q2 2025

Projected Impact: 7-day reduction = 63-day average (entering top quartile territory)

Understanding the Three Types of Benchmarking

Now that you’ve seen how it works in practice, let’s break down each type in detail.

1. Internal Benchmarking (You vs You)

What It Means

Internal benchmarking measures your own progress over time. It’s your personal baseline for improvement.

How to Apply It

• Track startup cycle times quarter-over-quarter
• Normalize for study type (Phase, therapeutic area, sponsor complexity)
• Highlight directional progress — not perfection

What Good Looks Like

Why Internal Benchmarking Matters

Even if you’re slower than the industry, internal benchmarking shows:

• Your process improvements are working
• Team changes are having an impact
• You’re moving in the right direction

It builds team morale and proves ROI on optimization efforts.

But internal trends only tell half the story. You might be improving quarter-over-quarter while still lagging the industry.

2. External Benchmarking (You vs Industry)

Why It Matters

You can’t gauge performance in a vacuum. External benchmarking tells you how you stack up against industry norms.

Sources to Use

• Tufts CSDD (2023): Median startup cycle ≈ 89 days
• TransCelerate BioPharma (2024): 25th–75th percentile range often 60–120 days
• CenterWatch (2024): High-performing sites average 20-30% faster than median
• Industry Reports: Top quartile sites consistently achieve 55-65 days for Phase 2-3 studies

How to Use It

Create a bar chart comparing your internal median (purple) vs industry median (gray).

What Good Looks Like

If you’re consistently above 100 days for Phase 2-3 studies, you’re in the slower half.

Phase-Specific External Benchmarks

Not all studies are equal. Here’s what competitive looks like by phase:

Even industry averages can mislead. A 90-day startup isn’t impressive if 40 days were wasted waiting.

3. Contextual Benchmarking (Efficiency over Duration)

Why Averages Mislead

Not all 90-day startups are equal. A 90-day timeline where 70 days are active work is far better than one with 50 days idle time.

What to Measure Instead

• % of total time in active work vs idle handoffs
• Stakeholder-specific latency (Sponsor, CRO, IRB, Site)
• Relative efficiency, not absolute duration

The Efficiency Formula

What Good Looks Like

Stakeholder-Specific Latency Tracking

Break down idle time by responsible party:

This pinpoints exactly where to focus optimization efforts.

Common Diagnostic Patterns: What Your Data Is Telling You

Here are the most common patterns we see and what they mean:

Benchmarking Pitfalls to Avoid

Don’t sabotage your analysis with these common mistakes:

1. Comparing Apples to Oranges

The mistake: Phase 1 oncology studies ≠ Phase 3 cardiology studies

Why it fails: Different phases have different complexity, regulatory requirements, and timelines.

Fix: Always segment by phase AND therapeutic area when comparing.

2. Ignoring Sponsor-Specific Delays

The mistake: Blaming yourself for delays outside your control

Example: Sponsor takes 30+ days for internal contract review

Why it matters: Some sponsors are systematically slower. This isn’t your fault.

Fix: Track “site-controlled days” vs “sponsor-controlled days” separately. Report on what you can control.

3. Celebrating Speed Without Efficiency

The mistake: Bragging about 60 days with 50% idle time

Reality: 70 days with 85% efficiency is better — it means you’re executing well when the ball is in your court.

Fix: Always report both total cycle time AND efficiency rate.

4. Using Stale Data

The mistake: Comparing your 2025 data to 2020-2021 benchmarks

Why it fails: Pandemic-era data is skewed. Post-COVID patterns are different.

Fix: Use benchmarks from 2023+. If using older data, note it clearly.

5. Focusing Only on Total Cycle Time

The mistake: “We’re at 75 days, we’re good!”

Reality: Without phase-by-phase breakdowns, you don’t know WHERE the delays are.

Fix: Break down by phase: Feasibility → Budget/Contract → IRB → Startup

6. Cherry-Picking Good Studies

The mistake: Only tracking your fastest studies

Reality: This inflates your performance and masks real problems.

Fix: Track ALL studies. If you need to exclude outliers, document why and report separately.

7. Not Adjusting for Study Complexity

The mistake: Comparing a simple observational study to a complex interventional trial

Fix: Create complexity tiers:

• Tier 1: Observational, registry studies
• Tier 2: Standard interventional
• Tier 3: High-complexity (gene therapy, rare disease, first-in-human)

Communicating Benchmarks to Stakeholders

Different audiences need different views of your benchmark data.

For Leadership

What they care about:

• Bottom line: Are we competitive?
• Trend: Are we improving?
• ROI: Are our investments working?

How to present:

Create a simple executive dashboard:

65 days
Average Startup Cycle Time
↑ 15% vs Last Quarter
Target: <60 days by Q2

27%
Faster than median
Rank: Top Quartile (25th %ile)

73%
Active Efficiency Rate
(Industry avg: 60%)
Status: Above Average ✓

Talking points:

• “We’re in the top 25% of sites nationally”
• “Our process improvements saved 20 days per study”
• “At our current volume, this represents $X in efficiency gains”

For Operations Teams

What they care about:

• Where are the bottlenecks?
• What can WE control?
• What’s the action plan?

How to present:

Create a phase-by-phase breakdown:

Phase	Our Time	Industry	Status	Owner
Feasibility	5 days	7 days	Fast	Clinical
Budget/Contract	22 days	18 days	Slow	Finance
IRB Submission	8 days	6 days	Slow	Regulatory
IRB Review	21 days	25 days	Fast	External
Startup Activities	9 days	12 days	Fast	Clinical

Action Items:

1. Finance: Investigate why budget/contract takes 22 vs 18 days
2. Regulatory: Streamline IRB submission prep (target: 6 days)
3. All: Maintain current performance in fast areas

For Sponsors (Building Credibility)

What they care about:

• Can this site deliver?
• Are they efficient?
• Will they meet timelines?

How to present:

Your 30-60-90 Day Benchmarking Action Plan

Ready to implement benchmarking at your site? Here’s your step-by-step plan:

FAQ: Your Benchmarking Questions Answered

Tools & Resources for Benchmarking

Free Public Benchmarks

Tools & Resources

Software and industry reports to power your benchmarking

Software Options

TrialConnx (shameless plug, but relevant)

• Automated startup tracking
• Built-in benchmark comparisons
• Real-time dashboards

CTMS Systems (Most have reporting)

• Advarra OnCore CTMS
• Oracle Siebel CTMS
• WCG eResearch CTMS
• Extract data for analysis

Business Intelligence Tools

• Tableau (advanced visualization)
• Power BI (Microsoft ecosystem)
• Google Data Studio (free)

Industry Reports Worth Buying

Annual Purchases ($500-1500 each):

• Tufts CSDD Outlook Report
• CenterWatch State of the Industry
• WCG IRB Benchmark Report
• SCRS member benchmarking data

ROI Calculation

If one report helps you shave 5 days off average startup, and you run 10 studies/year, that’s potentially 50 days of efficiency = easily worth $1000.

When Benchmarking Goes Wrong: Cautionary Tales

Takeaway

Benchmarking isn’t about bragging rights — it’s about clarity.

It tells you if your “fast” is actually efficient or just habitually slow.

You can’t improve what you haven’t compared.

The goal isn’t perfection. The goal is:

1. Know where you stand (internal + external context)
2. Identify opportunities (diagnostic patterns)
3. Take action (focused improvements)
4. Track progress (ongoing measurement)

Sites that benchmark systematically outperform those that don’t — not because measuring makes you faster, but because measurement drives focus, accountability, and continuous improvement.

What’s Next?

This post covered how to benchmark. Other Posts in this series – Metrics that matter:

• “5 Study Startup Metrics That Actually Predict Delays” (previous post)
• “How to Fix the Top 5 Study Startup Bottlenecks”
• “Building a Startup Metrics Dashboard Your Team Will Actually Use”

Want these delivered to your inbox? Subscribe to our study startup optimization series.

The post Benchmarking Study Startup — Internal vs External appeared first on TrialConnx.

Why Most Site Dashboards Fail (And What Yours Should Do Instead)

You’re tracking 15 different metrics across three sponsor portals. Your spreadsheet has 37 columns. You update it every Friday, and by Monday, you’ve already forgotten what half the numbers mean.

Sound familiar?

Here’s the problem: most site dashboards track everything except what matters. They show what already happened, not what’s about to go wrong.

The data backs this up. According to a 2024 analysis of NCI-designated cancer centers, study activation times range from 78 to 313 days. That’s a 235-day spread at institutions doing similar work.¹ The median time? 140.5 days for studies meeting the 70% activation threshold.²

But here’s what those numbers hide: roughly 40% of that time is idle. Waiting for handoffs. Waiting for someone to respond. Waiting for the next stage to start.

Your dashboard isn’t showing you that.

Over 85% of clinical trials face delays.³ For Phase III trials, every day of delay costs $36,000.⁴ But for sites? The cost isn’t just financial. It’s your PI losing patience. It’s your coordinator burning out. It’s that sponsor who won’t send you the next protocol.

Most dashboards show lagging indicators. What’s already done. They don’t predict what’s coming. You realize you’re behind schedule only after you’ve missed the milestone.

What sites actually need: leading indicators. Early warning signals that let you fix problems before they cascade.

The NCI recommends a 90-day “time to activation” as the gold standard.⁵ Most sites aren’t hitting it. The 2018 AACI benchmarking survey found a median activation time of 167 days across 61 cancer centers.⁶

The difference between 90 days and 167 days? It’s not lack of effort. It’s lack of visibility into the right metrics.

The 6 Cards That Make Up Your Minimal Viable Dashboard

Each metric answers one critical question. Track all six, and you’ll know if you’re on track before anyone asks.

1. Handoff Latency (Stage → Stage)

What it is: Time between completion of one stage and start of the next.

Why it matters for sites: Hidden delays accumulate here. If contracts close on Monday but regulatory doesn’t start until Thursday, you’ve lost three days. Do that five times during startup, and you’ve lost 15 days without anyone noticing.

How to track:

Benchmark: ≤2 business days

What “good” looks like: Contracts close Friday afternoon. Regulatory starts Monday morning. Handoff latency: 1 business day.

Site-specific tip: Map your handoffs across teams. Is feasibility waiting on the sponsor to respond? Is regulatory waiting on you to schedule the kickoff? Most sites don’t know where the delays actually happen because they track stage completion, not stage transitions.

“We thought we were slow at regulatory review. Turns out, we were fast, but contracts wasn’t handing off for 8 days after signature. Once we saw that, we fixed it in two weeks.”

— Regulatory Coordinator, 450-bed Academic Medical Center

2. Parallelization Index

What it is: Percentage of tasks running simultaneously instead of sequentially.

Why it matters for sites: You don’t have time to wait. If site training can happen while IRB is in review, you save weeks. If budget negotiations can run parallel to contract redlines, you save more.

The problem? Most sites work sequentially by habit, not necessity.

How to track:

Benchmark: ≥0.35 (35% of work runs in parallel)

What “good” looks like: Budget negotiations happen while regulatory preps the IRB submission. Pharmacy starts investigational product planning during feasibility. Training materials get developed before IRB approval (because you know it’s coming).

Site-specific tip: Look for tasks that don’t actually depend on each other. Can your pharmacy review the protocol before the budget is finalized? Can you draft informed consent while waiting on contract signature? Most sites serialize tasks that could run concurrently.

A community site managing eight studies increased their parallelization from 0.22 to 0.41 by starting training prep during regulatory review. Result: 12-day average time savings per study. Across eight studies, that’s 96 days (more than three months) of capacity gained.

3. Redline Iteration Count (Contracts & Budgets)

What it is: Number of review cycles for contracts and budgets before final signature.

Why it matters for sites: Every redline cycle adds 3-7 days. After four cycles, you’re looking at 12-28 days of delays. And here’s what nobody tells you: most of those delays aren’t about negotiation complexity. They’re about missing information upfront.

Academic medical centers currently take 8.12 months to activate studies compared to 4.37 months for independent sites (242% longer).⁷ A significant portion of that difference? Contract and budget cycles.

How to track: Count review cycles from first draft to final signature. Each exchange counts as one cycle.

Benchmark: ≤3 cycles

What “good” looks like: Draft → Sponsor review → Site legal revisions → Final signature = 3 cycles, completed in 14 days.

Site-specific tip: Track WHO causes delays. Is it sponsor legal every time? Your contracts office? Finance? Once you know the bottleneck, you can fix it. Maybe your finance team needs budget templates. Maybe sponsor legal needs pre-approved language. You can’t fix what you don’t measure.

Those numbers compound. If you’re running 10 studies per year and averaging 5 redline cycles instead of 3, you’re adding 130 days of delay across your portfolio. That’s four months of lost capacity.

4. IRB First-Pass Approval Rate

What it is: Percentage of IRB submissions approved without major revisions.

Why it matters for sites: IRB delays cascade. A first-pass approval means you’re activating in 4-6 weeks. Requiring revisions? You’re looking at 8-12 weeks. That’s a month of lost enrollment time.

IRB review times range from 13 to 116 days, with full board reviews taking 4-8 weeks.⁸ But here’s what matters: sites with high first-pass rates spend far less time in that range.

How to track:

Benchmark: ≥75%

What “good” looks like: Eight out of 10 submissions approved without major changes. The two that need revisions? Minor clarifications, not complete rewrites.

Site-specific tip: Track submission quality by coordinator. One person might have a 92% first-pass rate while another has 58%. That’s not a performance problem; it’s a training opportunity. Find out what the high performer does differently, then teach everyone else.

That site didn’t hire more staff. They created a 15-point pre-submission checklist. It takes 20 minutes to complete. It saved 16 days per study on average.

5. Feasibility Completeness Score

What it is: Percentage of required feasibility fields completed on first submission.

Why it matters for sites: Incomplete feasibility questionnaires delay selection decisions. And here’s the thing: you don’t get selected for the studies you submit late or incompletely. Sponsors move on to sites that responded faster and better.

How to track:

Benchmark: ≥95%

What “good” looks like: All PI credentials, coordinator contacts, regulatory timelines, patient volume estimates, and equipment availability documented. If the sponsor’s form doesn’t ask for something you know they need, include it anyway.

Site-specific tip: Create a master feasibility template with EVERY field a sponsor might want. PI CV? Already attached. Regulatory timeline estimate? Already filled in. Lab capabilities? Already documented. When a feasibility request comes in, you’re adapting a complete template, not starting from scratch.

Sites submitting at 98%+ completeness got selection decisions nine days faster and were selected 37 percentage points more often than sites below 90%. That’s the difference between being on the study and watching it go to your competitor down the street.

6. On-Time Startup Probability

What it is: Composite score predicting likelihood of hitting your target activation date.

Why it matters for sites: This gives you ONE number to answer “are we on track?” When your PI asks, when your director asks, when the sponsor asks, you have an answer backed by data, not gut feeling.

How to calculate: Weighted formula based on the five metrics above plus current stage progress.

Benchmark: ≥70% probability

What “good” looks like: All five metrics in green zones = 82% on-time probability. Two metrics in yellow = 64% probability. One metric in red = 41% probability.

Site-specific tip: If your probability drops below 60%, escalate immediately. Don’t wait for the sponsor to ask why you’re behind. Identify the bottleneck, propose a solution, and communicate proactively. That’s the difference between a trusted site partner and one that loses future opportunities.

“We review on-time probability every Monday morning. When Study 2407 dropped to 58%, we didn’t panic. We looked at the dashboard, saw the bottleneck was waiting on sponsor budget approval, and escalated. Got it resolved in 48 hours.”

— Site Director, Community Research Institute

How to Build This Dashboard in Under 1 Hour

You don’t need a developer. You don’t need expensive software. Here’s exactly how to set this up using a spreadsheet you already have.

Common Dashboard Mistakes to Avoid

Building a dashboard is easy. Building one your team actually uses? That takes discipline. Here are the mistakes that kill adoption.

Mistake #1: Tracking Too Many KPIs

Mistake #2: No SLA or Target Benchmarks

Mistake #3: No Clear Owner Per Metric

Mistake #4: Only Tracking Lagging Indicators

Most dashboards show what already happened: “IRB approved on 3/15.” That’s useful for documentation, not for preventing delays.

The fix: Add leading indicators like handoff latency and parallelization that predict delays before they compound.

Mistake #5: Manual Updates Once a Week

If updating the dashboard takes 45 minutes every Friday, it won’t last. People will skip it when they’re busy, which is exactly when you need it most.

The fix: Use formulas or automation so the dashboard updates when you enter stage dates. If you’re using a system like TrialConnx, it happens automatically.

Mistake #6: Confusing Color Scheme

Random colors confuse people. Blue for good, red for bad, green for… medium? Nobody knows what they’re looking at.

The fix: Stick to a consistent scheme. Green = on target, yellow = needs attention, red = critical. Use brand colors where appropriate (purple for emphasis, not status).

Frequently Asked Questions

Next Steps: Implement This Month

Don’t wait for the perfect time. Start this week. Here’s your four-week implementation plan.

That’s it. Four weeks. One metric at a time. Real improvement, not perfection.

The post The Minimal Viable Study Startup Dashboard – Only 6 Metrics You Need appeared first on TrialConnx.